Logos Global Management LP Lineage Cell Therapeutics, Inc. Transaction History
Logos Global Management LP
- $756 Million
- Q3 2024
A detailed history of Logos Global Management LP transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Logos Global Management LP holds 5,000,000 shares of LCTX stock, worth $3.2 Million. This represents 0.6% of its overall portfolio holdings.
Number of Shares
5,000,000
Previous 4,700,000
6.38%
Holding current value
$3.2 Million
Previous $4.7 Million
3.19%
% of portfolio
0.6%
Previous 0.44%
Shares
3 transactions
Others Institutions Holding LCTX
# of Institutions
121Shares Held
94.2MCall Options Held
63.8KPut Options Held
1K-
Broadwood Capital Inc New York, NY41.7MShares$26.7 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$6.12 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.6MShares$5.5 Million0.0% of portfolio
-
Defender Capital, Llc.5MShares$3.2 Million1.58% of portfolio
-
Raffles Associates LP New York, NY4.51MShares$2.88 Million4.64% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $109M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...